Loading
Pyxis Oncology
A listed Boston company developing an antibody-drug conjugate, a drug that carries a toxin into the tumour, aimed at a protein found in the tissue around cancers. It is in early trials, mainly for head and neck cancer that has come back or spread.
Also called: Pyxis Oncology, Inc.Pyxis Oncology, Inc
Overview
Pyxis Oncology develops antibody-drug conjugates and immunotherapy antibodies. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an ADC with an auristatin payload that targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tumour's extracellular matrix rather than a protein on the cancer cell. It is in Phase 1 as a single agent (NCT05720117) and with pembrolizumab (NCT06795412, Phase 1/2, with Merck Sharp & Dohme as collaborator), with a focus on recurrent or metastatic head and neck squamous cell carcinoma. The company says the FDA granted Fast Track designation for R/M HNSCC that has progressed after platinum chemotherapy and an anti-PD-(L)1 therapy. Pyxis trades on Nasdaq under PYXS according to its SEC filings.
Headquarters
Boston, MA, US
Scorecard
All companies#655of 1706 companies, score 5
- phase 1/2 +1
- targets +2
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Type
Biotech · NASDAQ: PYXS
Stage
Public
Website
Products
1Phase 1Antibody-drug conjugate (auristatin payload)
Micvotabart pelidotin is an experimental antibody-drug conjugate from Pyxis Oncology, in phase 1 trials for advanced solid tumours, with a focus on recurrent or metastatic head and neck squamous cell carcinoma.
Notes
- Founding year not stated on the pages read.
- The FN1 target link is for EDB+FN, a splice variant of fibronectin 1.
- NCT05720117 was confirmed through the ClinicalTrials.gov v2 API but is not yet a trial record in OnCo.
Connected
8Similar pages
- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Antibody-drug conjugate (ADC).
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Antibody-drug conjugate (ADC).
- CompanyStipple Bio
Shares RA Capital Management, Antibody-drug conjugate (ADC).
- CompanyAdcytherix
Shares RA Capital Management, Antibody-drug conjugate (ADC).
- CompanyBiohaven
Shares RA Capital Management, Antibody-drug conjugate (ADC).
- CompanyAlentis Therapeutics
Shares RA Capital Management, Antibody-drug conjugate (ADC).
- CompanyAdcendo
Shares RA Capital Management, Antibody-drug conjugate (ADC).
cancers
fronts
technologies
targets
drugs
Phase 1Antibody-drug conjugate (auristatin payload)
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 2
pyxisoncology.com · 2
racap.com · 1
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/